Generic for Emend: Aprepitant

Yes. The generic name for Emend is aprepitant. 12 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB, AP. Generics match 4 of the 6 Emend products the Orange Book lists.

Run it in Rivvi

Map Emend and your other top fills to their generics

Every strength in RxNorm, with brands that have no generic flagged.

Build the map

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Emend products in the Orange Book

Emend products and approved generics
Form and route	Strength	Brand status	Brand TE	Active generics	Generic TE codes
capsule, oral	125MG	Marketed (Rx)	AB	3	AB
capsule, oral	40MG	Discontinued	None	3	AB
capsule, oral	80MG	Marketed (Rx)	AB	3	AB
for suspension, oral	125MG/KIT	Discontinued	None	0	None
powder, intravenous	EQ 115MG BASE/VIAL	Discontinued	None	0	None
powder, intravenous	EQ 150MG BASE/VIAL	Marketed (Rx)	AP	9	AP

NDA 021549, 207865, 022023, held by MERCK SHARP AND DOHME LLC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.

Approved generic aprepitant

Approved generic versions of Emend
Company	ANDA	TE code	Approved	Strengths
SANDOZ INC	090999	AB (A-rated, therapeutically equivalent)	September 24, 2012	125MG, 40MG, 80MG
FRESENIUS KABI USA LLC	206197	AP (A-rated, therapeutically equivalent)	June 9, 2016	EQ 150MG BASE/VIAL
GLENMARK SPECIALTY SA	207777	AB (A-rated, therapeutically equivalent)	October 12, 2017	125MG, 40MG, 80MG
BE PHARMACEUTICALS AG	212309	AP (A-rated, therapeutically equivalent)	September 5, 2019	EQ 150MG BASE/VIAL
MSN LABORATORIES PRIVATE LTD	209965	AP (A-rated, therapeutically equivalent)	September 5, 2019	EQ 150MG BASE/VIAL
MYLAN LABORATORIES LTD	204015	AP (A-rated, therapeutically equivalent)	September 5, 2019	EQ 150MG BASE/VIAL
QILU PHARMACEUTICAL HAINAN CO LTD	213106	AP (A-rated, therapeutically equivalent)	September 8, 2020	EQ 150MG BASE/VIAL
TORRENT PHARMA INC	211835	AB (A-rated, therapeutically equivalent)	October 21, 2020	125MG, 40MG, 80MG
DR REDDYS LABORATORIES LTD	211160	AP (A-rated, therapeutically equivalent)	December 9, 2020	EQ 150MG BASE/VIAL
EUGIA PHARMA SPECIALITIES LTD	210625	AP (A-rated, therapeutically equivalent)	January 12, 2021	EQ 150MG BASE/VIAL
CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD	212143	AP (A-rated, therapeutically equivalent)	March 3, 2021	EQ 150MG BASE/VIAL
ASPIRO PHARMA LTD	214616	AP (A-rated, therapeutically equivalent)	July 29, 2021	EQ 150MG BASE/VIAL

Emend patents

Patents listed for Emend
Patent	Expires	Covers	Use code	NDA
8258132	September 26, 2027	Drug product	U-901	021549
8258132	September 26, 2027	Drug product	U-1743	021549
8258132	September 26, 2027	Drug product	U-1916	207865

Emend NDC codes

Questions

Is there a generic for Emend?

Yes. The generic name for Emend is aprepitant. 12 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB, AP. Generics match 4 of the 6 Emend products the Orange Book lists.

What is the generic name for Emend?

The active ingredient in Emend is aprepitant, per the FDA Orange Book.

When does the Emend patent expire?

The last patent listed for Emend in the Orange Book expires September 26, 2027. A listed patent expiry date is not a generic launch date.

What does a therapeutic equivalence code mean?

In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.

Generic for Emend